Synthetic lethality to overcome cancer drug resistance

Current Medicinal Chemistry

Volumn 19, Issue 23, 2012, Pages 3858-3873

  Porcelli, L ^a   Quatrale, A E ^a   Mantuano, P ^a   Silvestris, N ^a   Brunetti, A E ^a   Calvert, H ^b   Paradiso, A ^a   Azzariti, A ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anticancer therapy; DNA repair pathway; Drug resistance; PARP inhibitors; Solid tumors; Synthetic lethality

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANTINEOPLASTIC AGENT; AVAGACESTAT; BEGACESTAT; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CETUXIMAB; CISPLATIN; CONATUMUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; E 2012; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; INIPARIB; IRINOTECAN; LAPATINIB; METHOTREXATE; MK 0752; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PF 3084014; SEMAGACESTAT; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; TIGATUZUMAB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL VIABILITY; COLON CANCER; COLORECTAL CANCER; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; EXCISION REPAIR; GENE MUTATION; GLIOBLASTOMA; HUMAN; INTRAOPERATIVE RADIOTHERAPY; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MISMATCH REPAIR; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NEUROBLASTOMA; NONHUMAN; ONCOGENE RAS; OVARY CANCER; PANCREAS CANCER; PARTIAL MASTECTOMY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEGMENTAL MASTECTOMY; SINGLE STRANDED DNA BREAK; SOLID TUMOR; SYNTHETIC LETHALITY; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, DEATH DOMAIN;

EID: 84865720100     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802002563     Document Type: Article

References (172)

1. Azzariti, A.; Porcelli, L.; Paradiso, A. In Multidrug Resistance : Biological and Pharmaceutical Advance in the Antitumour Treatment: Chapter 1-Clinical relevance of Multi Drug Resistance in chemotherapic treatment; Colabufo AN: 2008;, pp 1-18.
2. Ling, V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 1997, 40 Suppl, S3-8.
3. Iglehart, J. D.; Silver, D. P. Synthetic lethality- A new direction in cancerdrug development. N. Engl. J. Med. 2009, 361, 189-191.
4. Nijman, S. M. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 2011, 585, 1-6.
5. Brough, R.; Frankum, J. R.; Costa-Cabral, S.; Lord, C. J.; Ashworth, A. Searching for synthetic lethality in cancer. Curr. Opin. Genet. Dev. 2011, 21, 34-41.
6. Park, Y.; Kitahara, T.; Takagi, R.; Kato, R. Current status of therapy for breast cancer worldwide and in Japan. World J. Clin. Oncol. 2011, 2, 125-134.
7. Lyons, J. A.; Woods, C.; Galanopoulos, N.; Silverman, P. Emerging radiation techniques for early-stage breast cancer after breast-conserving surgery. Future Oncol. 2011, 7, 915-925.
8. Moore, A. Breast-cancer therapy-looking back to the future. N. Engl. J. Med. 2007, 357, 1547-1549.
9. Toft, D. J.; Cryns, V. L. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol. Endocrinol. 2011, 25, 199-211.
10. Calvert, H.; Azzariti, A. The clinical development of inhibitors of poly(ADPribose) polymerase. Ann. Oncol. 2011, 22 Suppl 1, i53-9.
11. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer. 2004, 4, 814-819. (Pubitemid 39331153)
12. O'Shaughnessy, J.; Osborne, C.; Pippen, J. E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, I. C.; Sherman, B. M.; Bradley, C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011, 364, 205-214.
13. New, J. H.; Sugiyama, T.; Zaitseva, E.; Kowalczykowski, S. C. Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A. Nature 1998, 391, 407-410. (Pubitemid 28093518)
14. Sung, P. Function of yeast Rad52 protein as a mediator between replication protein A and the Rad51 recombinase. J. Biol. Chem. 1997, 272, 28194-28197. (Pubitemid 27517755)
15. Shinohara, A.; Ogawa, T. Stimulation by Rad52 of yeast Rad51-mediated recombination. Nature 1998, 391, 404-407. (Pubitemid 28093517)
16. Feng, Z.; Scott, S. P.; Bussen, W.; Sharma, G. G.; Guo, G.; Pandita, T. K.; Powell, S. N. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 686-691.
17. Peng, G.; Yim, E. K.; Dai, H.; Jackson, A. P.; Burgt, I.; Pan, M. R.; Hu, R.; Li, K.; Lin, S. Y. BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nat. Cell Biol. 2009, 11, 865-872.
18. Lin, S. Y.; Liang, Y.; Li, K. Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression. Yonsei Med. J. 2010, 51, 295-301.
19. Rehman, F. L.; Lord, C. J.; Ashworth, A. Synthetic lethal approaches to breast cancer therapy. Nat. Rev. Clin. Oncol. 2010, 7, 718-724.
20. Hynes, N. E.; Stoelzle, T. Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res. 2009, 11, 210.
21. Xu, J.; Chen, Y.; Olopade, O. I. MYC and Breast Cancer. Genes Cancer. 2010, 1, 629-640.
22. Aulmann, S.; Adler, N.; Rom, J.; Helmchen, B.; Schirmacher, P.; Sinn, H. P. C-Myc Amplifications in Primary Breast Carcinomas and their Local Recurrences. J. Clin. Pathol. 2006, 59, 424-428.
23. Bieche, I.; Laurendeau, I.; Tozlu, S.; Olivi, M.; Vidaud, D.; Lidereau, R.; Vidaud, M. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 1999, 59, 2759-2765. (Pubitemid 29283103)
24. Naidu, R.; Wahab, N. A.; Yadav, M.; Kutty, M. K. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int. J. Mol. Med. 2002, 9, 189-196.
25. Zhang, X. Y.; Pfeiffer, H. K.; Mellert, H. S.; Stanek, T. J.; Sussman, R. T.; Kumari, A.; Yu, D.; Rigoutsos, I.; Thomas-Tikhonenko, A.; Seidel, H. E.; Chodosh, L. A.; Packham, G.; Baserga, R.; McMahon, S. B. Inhibition of the Single Downstream Target BAG1 Activates the Latent Apoptotic Potential of MYC. Mol. Cell. Biol. 2011, 31, 5037-5045.
26. Wang, Y.; Engels, I. H.; Knee, D. A.; Nasoff, M.; Deveraux, Q. L.; Quon, K. C. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer. Cell. 2004, 5, 501-512. (Pubitemid 38610251)
27. Nadler, Y.; Camp, R. L.; Giltnane, J. M.; Moeder, C.; Rimm, D. L.; Kluger, H. M.; Kluger, Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res. 2008, 10, R35.
28. Tang, S. C.; Beck, J.; Murphy, S.; Chernenko, G.; Robb, D.; Watson, P.; Khalifa, M. BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma. Breast Cancer Res. Treat. 2004, 84, 203-213. (Pubitemid 38445370)
29. Townsend, P. A.; Dublin, E.; Hart, I. R.; Kao, R. H.; Hanby, A. M.; Cutress, R. I.; Poulsom, R.; Ryder, K.; Barnes, D. M.; Packham, G. BAG-i expression in human breast cancer: interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-athological data. J. Pathol. 2002, 197, 51-59. (Pubitemid 34450164)
30. Evan, G. I.; Wyllie, A. H.; Gilbert, C. S.; Littlewood, T. D.; Land, H.; Brooks, M.; Waters, C. M.; Penn, L. Z.; Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69, 119-128.
31. Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455, 679-683.
32. Sharp, A.; Crabb, S. J.; Johnson, P. W.; Hague, A.; Cutress, R.; Townsend, P. A.; Ganesan, A.; Packham, G. Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-rotein interactions. J. Pharmacol. Exp. Ther. 2009, 331, 680-689.
33. Smyth, M. J.; Takeda, K.; Hayakawa, Y.; Peschon, J. J.; van den Brink, M. R.; Yagita, H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003, 18, 1-6. (Pubitemid 36120682)
34. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer. 2002, 2, 420-430. (Pubitemid 37328939)
35. Sebastian, S.; Settleman, J.; Reshkin, S. J.; Azzariti, A.; Bellizzi, A.; Paradiso, A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 2006, 1766, 120-139.
36. Quatrale, A. E.; Petriella, D.; Porcelli, L.; Tommasi, S.; Silvestris, N.; Colucci, G.; Angelo, A.; Azzariti, A. Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Front. Biosci. 2011, 16, 1973-1985.
37. Quatrale, A. E.; Porcelli, L.; Silvestris, N.; Colucci, G.; Angelo, A.; Azzariti, A. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front. Biosci. 2011, 16, 1962-1972.
38. Jhappan, C.; Gallahan, D.; Stahle, C.; Chu, E.; Smith, G. H.; Merlino, G.; Callahan, R. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev. 1992, 6, 345-355.
39. Dievart, A.; Beaulieu, N.; Jolicoeur, P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999, 18, 5973-5981. (Pubitemid 29535009)
40. Nickoloff, B. J.; Hendrix, M. J.; Pollock, P. M.; Trent, J. M.; Miele, L.; Qin, J. Z. Notch and NOXA-related pathways in melanoma cells. J. Investig. Dermatol. Symp. Proc. 2005, 10, 95-104.
41. Fortini, M. E. Notch signaling: the core pathway and its posttranslational regulation. Dev. Cell. 2009, 16, 633-647.
42. Mungamuri, S. K.; Yang, X.; Thor, A. D.; Somasundaram, K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006, 66, 4715-4724.
43. Meurette, O.; Stylianou, S.; Rock, R.; Collu, G. M.; Gilmore, A. P.; Brennan, K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res. 2009, 69, 5015-5022.
44. Lee, C. W.; Raskett, C. M.; Prudovsky, I.; Altieri, D. C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008, 68, 5273-5281.
45. Osipo, C.; Patel, P.; Rizzo, P.; Clementz, A. G.; Hao, L.; Golde, T. E.; Miele, L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008, 27, 5019-5032.
46. Han, J.; Ma, I.; Hendzel, M. J.; Allalunis-Turner, J. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. Breast Cancer Res. 2009, 11, R57.
47. Konishi, J.; Yi, F.; Chen, X.; Vo, H.; Carbone, D. P.; Dang, T. P. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene 2010, 29, 589-596.
48. Kolev, V.; Mandinova, A.; Guinea-Viniegra, J.; Hu, B.; Lefort, K.; Lambertini, C.; Neel, V.; Dummer, R.; Wagner, E. F.; Dotto, G. P. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat. Cell Biol. 2008, 10, 902-911.
49. Purow, B. W.; Sundaresan, T. K.; Burdick, M. J.; Kefas, B. A.; Comeau, L. D.; Hawkinson, M. P.; Su, Q.; Kotliarov, Y.; Lee, J.; Zhang, W.; Fine, H. A. Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis 2008, 29, 918-925. (Pubitemid 351982234)
50. Dong, Y.; Li, A.; Wang, J.; Weber, J. D.; Michel, L. S. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 2010, 70, 5465-5474.
51. Sergina, N. V.; Rausch, M.; Wang, D.; Blair, J.; Hann, B.; Shokat, K. M.; Moasser, M. M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445, 437-441. (Pubitemid 46160912)
52. Johnston, S. R. New strategies in estrogen receptor-ositive breast cancer. Clin. Cancer Res. 2010, 16, 1979-1987.
53. Creighton, C. J.; Hilger, A. M.; Murthy, S.; Rae, J. M.; Chinnaiyan, A. M.; El-Ashry, D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-ositive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006, 66, 3903-3911.
54. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer. Ther. 2002, 1, 707-717.
55. Faridi, J.; Wang, L.; Endemann, G.; Roth, R. A. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin. Cancer Res. 2003, 9, 2933-2939. (Pubitemid 36993252)
56. Campbell, R. A.; Bhat-Nakshatri, P.; Patel, N. M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 2001, 276, 9817-9824.
57. deGraffenried, L. A.; Friedrichs, W. E.; Russell, D. H.; Donzis, E. J.; Middleton, A. K.; Silva, J. M.; Roth, R. A.; Hidalgo, M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res. 2004, 10, 8059-8067. (Pubitemid 39587547)
58. DeGraffenried, L. A.; Fulcher, L.; Friedrichs, W. E.; Grunwald, V.; Ray, R. B.; Hidalgo, M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 2004, 15, 1510-1516. (Pubitemid 39409742)
59. Boulay, A.; Rudloff, J.; Ye, J.; Zumstein-Mecker, S.; O'Reilly, T.; Evans, D. B.; Chen, S.; Lane, H. A. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 2005, 11, 5319-5328. (Pubitemid 41003721)
60. Beeram, M.; Tan, Q. T.; Tekmal, R. R.; Russell, D.; Middleton, A.; DeGraffenried, L. A. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol. 2007, 18, 1323-1328. (Pubitemid 47305004)
61. Miller, T. W.; Hennessy, B. T.; Gonzalez-Angulo, A. M.; Fox, E. M.; Mills, G. B.; Chen, H.; Higham, C.; Garcia-Echeverria, C.; Shyr, Y.; Arteaga, C. L. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-ositive human breast cancer. J. Clin. Invest. 2010, 120, 2406-2413.
62. Crowder, R. J.; Phommaly, C.; Tao, Y.; Hoog, J.; Luo, J.; Perou, C. M.; Parker, J. S.; Miller, M. A.; Huntsman, D. G.; Lin, L.; Snider, J.; Davies, S. R.; Olson, J. A.,Jr; Watson, M. A.; Saporita, A.; Weber, J. D.; Ellis, M. J. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-ositive breast cancer. Cancer Res. 2009, 69, 3955-3962.
63. Shih, I.; Kurman, R. J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004, 164, 1511-1518. (Pubitemid 38529752)
64. Singer, G.; Oldt, R.,3rd; Cohen, Y.; Wang, B. G.; Sidransky, D.; Kurman, R. J.; Shih, I. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 2003, 95, 484-486.
65. Milner, B. J.; Allan, L. A.; Eccles, D. M.; Kitchener, H. C.; Leonard, R. C.; Kelly, K. F.; Parkin, D. E.; Haites, N. E. P53 Mutation is a Common Genetic Event in Ovarian Carcinoma. Cancer Res. 1993, 53, 2128-2132. (Pubitemid 23145738)
66. Bowtell, D. D. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer. 2010, 10, 803-808.
67. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
68. Tan, D. S.; Rothermundt, C.; Thomas, K.; Bancroft, E.; Eeles, R.; Shanley, S.; Ardern-Jones, A.; Norman, A.; Kaye, S. B.; Gore, M. E. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 2008, 26, 5530-5536.
69. Mukhopadhyay, A.; Curtin, N.; Plummer, R.; Edmondson, R. J. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. BJOG 2011, 118, 429-432.
70. Weberpals, J. I.; Koti, M.; Squire, J. A. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer. Genet. 2011, 204, 525-535.
71. Pal, T.; Permuth-Wey, J.; Betts, J. A.; Krischer, J. P.; Fiorica, J.; Arango, H.; LaPolla, J.; Hoffman, M.; Martino, M. A.; Wakeley, K.; Wilbanks, G.; Nicosia, S.; Cantor, A.; Sutphen, R. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005, 104, 2807-2816. (Pubitemid 41798292)
72. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H.; de Bono, J. S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361, 123-134.
73. Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R. K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376, 245-251.
74. Mukhopadhyay, A.; Elattar, A.; Cerbinskaite, A.; Wilkinson, S. J.; Drew, Y.; Kyle, S.; Los, G.; Hostomsky, Z.; Edmondson, R. J.; Curtin, N. J. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 2010, 16, 2344-2351.
75. Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA doublestrand break repair. J. Clin. Oncol. 2008, 26, 3785-3790.
76. Gelmon, K. A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; Yerushalmi, R.; Macpherson, E.; Carmichael, J.; Oza, A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study. Lancet Oncol. 2011, 12, 852-861.
77. Westphal, M.; Lamszus, K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat. Rev. Neurosci. 2011, 12, 495-508.
78. Lefranc, F.; Rynkowski, M.; DeWitte, O.; Kiss, R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv. Tech. Stand. Neurosurg. 2009, 34, 3-35.
79. de Groot, J. F.; Gilbert, M. R. New molecular targets in malignant gliomas. Curr. Opin. Neurol. 2007, 20, 712-718. (Pubitemid 350085016)
80. D'Atri, S.; Tentori, L.; Lacal, P. M.; Graziani, G.; Pagani, E.; Benincasa, E.; Zambruno, G.; Bonmassar, E.; Jiricny, J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol. 1998, 54, 334-341. (Pubitemid 28368823)
81. Cheng, C. L.; Johnson, S. P.; Keir, S. T.; Quinn, J. A.; Ali-Osman, F.; Szabo, C.; Li, H.; Salzman, A. L.; Dolan, M. E.; Modrich, P.; Bigner, D. D.; Friedman, H. S. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol. Cancer. Ther. 2005, 4, 1364-1368.
82. Fukushima, T.; Takeshima, H.; Kataoka, H. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 2009, 29, 4845-4854.
83. Tentori, L.; Leonetti, C.; Scarsella, M.; D'Amati, G.; Vergati, M.; Portarena, I.; Xu, W.; Kalish, V.; Zupi, G.; Zhang, J.; Graziani, G. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 2003, 9, 5370-5379. (Pubitemid 37413592)
84. Plummer, E. R. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr. Opin. Pharmacol. 2006, 6, 364-368. (Pubitemid 44040837)
85. Tentori, L.; Leonetti, C.; Scarsella, M.; Vergati, M.; Xu, W.; Calvin, D.; Morgan, L.; Tang, Z.; Woznizk, K.; Alemu, C.; Hoover, R.; Lapidus, R.; Zhang, J.; Graziani, G. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int. J. Oncol. 2005, 26, 415-422.
86. McEllin, B.; Camacho, C. V.; Mukherjee, B.; Hahm, B.; Tomimatsu, N.; Bachoo, R. M.; Burma, S. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 2010, 70, 5457-5464.
87. Demuth, T.; Reavie, L. B.; Rennert, J. L.; Nakada, M.; Nakada, S.; Hoelzinger, D. B.; Beaudry, C. E.; Henrichs, A. N.; Anderson, E. M.; Berens, M. E. MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol. Cancer. Ther. 2007, 6, 1212-1222. (Pubitemid 46711984)
88. Kim, Y. W.; Liu, T. J.; Koul, D.; Tiao, N.; Feroze, A. H.; Wang, J.; Powis, G.; Yung, W. K. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol. 2011, 13, 367-375.
89. Masica, D. L.; Karchin, R. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res. 2011, 71, 4550-4561.
90. Degenhardt, Y.; Greshock, J.; Laquerre, S.; Gilmartin, A. G.; Jing, J.; Richter, M.; Zhang, X.; Bleam, M.; Halsey, W.; Hughes, A.; Moy, C.; Liu-Sullivan, N.; Powers, S.; Bachman, K.; Jackson, J.; Weber, B.; Wooster, R. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol. Cancer. Ther. 2010, 9, 2079-2089.
91. Bell, E.; Chen, L.; Liu, T.; Marshall, G. M.; Lunec, J.; Tweddle, D. A. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010, 293, 144-157.
92. Fechete, R.; Barth, S.; Olender, T.; Munteanu, A.; Bernthaler, A.; Inger, A.; Perco, P.; Lukas, A.; Lancet, D.; Cinatl, J.,Jr; Michaelis, M.; Mayer, B. Synthetic lethal hubs associated with vincristine resistant neuroblastoma. Mol. Biosyst 2011, 7, 200-214.
93. Molenaar, J. J.; Ebus, M. E.; Geerts, D.; Koster, J.; Lamers, F.; Valentijn, L. J.; Westerhout, E. M.; Versteeg, R.; Caron, H. N. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 12968-12973.
94. Zochbauer-Muller, S.; Gazdar, A. F.; Minna, J. D. Molecular pathogenesis of lung cancer. Annu. Rev. Physiol. 2002, 64, 681-708. (Pubitemid 34259246)
95. Wilson, P. M.; Labonte, M. J.; Lenz, H. J.; Mack, P. C.; Ladner, R. D. Inhibition of dUTPase induces synthetic lethality with thymidylate synthasetargeted therapies in non-small cell lung cancer. Mol. Cancer. Ther. 2011.
96. Ladner, R. D.; Lynch, F. J.; Groshen, S.; Xiong, Y. P.; Sherrod, A.; Caradonna, S. J.; Stoehlmacher, J.; Lenz, H. J. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res. 2000, 60, 3493-3503. (Pubitemid 30482169)
97. Barbie, D. A.; Tamayo, P.; Boehm, J. S.; Kim, S. Y.; Moody, S. E.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Meylan, E.; Scholl, C.; Frohling, S.; Chan, E. M.; Sos, M. L.; Michel, K.; Mermel, C.; Silver, S. J.; Weir, B. A.; Reiling, J. H.; Sheng, Q.; Gupta, P. B.; Wadlow, R. C.; Le, H.; Hoersch, S.; Wittner, B. S.; Ramaswamy, S.; Livingston, D. M.; Sabatini, D. M.; Meyerson, M.; Thomas, R. K.; Lander, E. S.; Mesirov, J. P.; Root, D. E.; Gilliland, D. G.; Jacks, T.; Hahn, W. C. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462, 108-112.
98. Moffat, J.; Grueneberg, D. A.; Yang, X.; Kim, S. Y.; Kloepfer, A. M.; Hinkle, G.; Piqani, B.; Eisenhaure, T. M.; Luo, B.; Grenier, J. K.; Carpenter, A. E.; Foo, S. Y.; Stewart, S. A.; Stockwell, B. R.; Hacohen, N.; Hahn, W. C.; Lander, E. S.; Sabatini, D. M.; Root, D. E. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124, 1283-1298.
99. Paul, I.; Savage, K. I.; Blayney, J. K.; Lamers, E.; Gately, K.; Kerr, K.; Sheaff, M.; Arthur, K.; Richard, D. J.; Hamilton, P. W.; James, J. A.; O'Byrne, K. J.; Harkin, D. P.; Quinn, J. E.; Fennell, D. A. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient nonsmall cell lung cancer. J. Pathol. 2011, 224, 564-574.
100. Crawford, N.; Chacko, A. D.; Savage, K. I.; McCoy, F.; Redmond, K.; Longley, D. B.; Fennell, D. A. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis 2011, 16, 311-320.
101. Olaussen, K. A.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H. H.; Stahel, R.; Sabatier, L.; Pignon, J. P.; Tursz, T.; Le Chevalier, T.; Soria, J. C.; IALT Bio Investigators DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355, 983-991. (Pubitemid 44343542)
102. Gorgoulis, V. G.; Vassiliou, L. V.; Karakaidos, P.; Zacharatos, P.; Kotsinas, A.; Liloglou, T.; Venere, M.; Ditullio, R. A.,Jr; Kastrinakis, N. G.; Levy, B.; Kletsas, D.; Yoneta, A.; Herlyn, M.; Kittas, C.; Halazonetis, T. D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434, 907-913. (Pubitemid 40559004)
103. Bartkova, J.; Horejsi, Z.; Koed, K.; Kramer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J. M.; Lukas, C.; Orntoft, T.; Lukas, J.; Bartek, J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434, 864-870. (Pubitemid 40558993)
104. Gilad, O.; Nabet, B. Y.; Ragland, R. L.; Schoppy, D. W.; Smith, K. D.; Durham, A. C.; Brown, E. J. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010, 70, 9693-9702.
105. Mader, R. M.; Muller, M.; Steger, G. G. Resistance to 5-fluorouracil. Gen. Pharmacol. 1998, 31, 661-666. (Pubitemid 28520040)
106. Grem, J. L.; Danenberg, K. D.; Behan, K.; Parr, A.; Young, L.; Danenberg, P. V.; Nguyen, D.; Drake, J.; Monks, A.; Allegra, C. J. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin. Cancer Res. 2001, 7, 999-1009. (Pubitemid 32708739)
107. Evrard, A.; Cuq, P.; Ciccolini, J.; Vian, L.; Cano, J. P. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br. J. Cancer 1999, 80, 1726-1733. (Pubitemid 29389624)
108. Takebe, N.; Zhao, S. C.; Ural, A. U.; Johnson, M. R.; Banerjee, D.; Diasio, R. B.; Bertino, J. R. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001, 8, 966-973. (Pubitemid 33140315)
109. Rose, M. G.; Farrell, M. P.; Schmitz, J. C. Thymidylate synthase: a critical target for cancer chemotherapy. Clin. Colorectal Cancer. 2002, 1, 220-229. (Pubitemid 34269382)
110. Johnston, P. G.; Lenz, H. J.; Leichman, C. G.; Danenberg, K. D.; Allegra, C. J.; Danenberg, P. V.; Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995, 55, 1407-1412.
111. Allegra, C. Thymidylate synthase levels: prognostic, predictive, or both? J. Clin. Oncol. 2002, 20, 1711-1713.
112. Giovannetti, E.; Backus, H. H.; Wouters, D.; Ferreira, C. G.; van Houten, V. M.; Brakenhoff, R. H.; Poupon, M. F.; Azzarello, A.; Pinedo, H. M.; Peters, G. J. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br. J. Cancer 2007, 96, 769-775. (Pubitemid 46376640)
113. Meyers, M.; Hwang, A.; Wagner, M. W.; Bruening, A. J.; Veigl, M. L.; Sedwick, W. D.; Boothman, D. A. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 2003, 22, 7376-7388.
114. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. P53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents. Cell 1993, 74, 957-967. (Pubitemid 23289454)
115. Bunz, F.; Hwang, P. M.; Torrance, C.; Waldman, T.; Zhang, Y.; Dillehay, L.; Williams, J.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999, 104, 263-269.
116. Reichard, P. Interactions between deoxyribonucleotide and DNA synthesis. Annu. Rev. Biochem. 1988, 57, 349-374.
117. Hu, C. M.; Chang, Z. F. Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status. Cancer Res. 2008, 68, 2831-2840.
118. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. P53 Mutations in Human Cancers. Science 1991, 253, 49-53. (Pubitemid 21917115)
119. Samowitz, W. S.; Curtin, K.; Schaffer, D.; Robertson, M.; Leppert, M.; Slattery, M. L. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 1193-1197.
120. Ogino, S.; Nosho, K.; Kirkner, G. J.; Kawasaki, T.; Meyerhardt, J. A.; Loda, M.; Giovannucci, E. L.; Fuchs, C. S. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58, 90-96.
121. Cully, M.; Downward, J. SnapShot: Ras Signaling. Cell 2008, 133, 1292-1292.e1.
122. Wang, Y.; Ngo, V. N.; Marani, M.; Yang, Y.; Wright, G.; Staudt, L. M.; Downward, J. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010, 29, 4658-4670.
123. Luo, J.; Emanuele, M. J.; Li, D.; Creighton, C. J.; Schlabach, M. R.; Westbrook, T. F.; Wong, K. K.; Elledge, S. J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137, 835-848.
124. Steegmaier, M.; Hoffmann, M.; Baum, A.; Lenart, P.; Petronczki, M.; Krssak, M.; Gurtler, U.; Garin-Chesa, P.; Lieb, S.; Quant, J.; Grauert, M.; Adolf, G. R.; Kraut, N.; Peters, J. M.; Rettig, W. J. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 2007, 17, 316-322. (Pubitemid 46241881)
125. Eldridge, A. G.; Loktev, A. V.; Hansen, D. V.; Verschuren, E. W.; Reimann, J. D.; Jackson, P. K. The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-romoting complex inhibitor emi1. Cell 2006, 124, 367-380. (Pubitemid 43121984)
126. Peterson, J. R.; Mitchison, T. J. Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. Chem. Biol. 2002, 9, 1275-1285. (Pubitemid 36010683)
127. Martin, S. A.; McCarthy, A.; Barber, L. J.; Burgess, D. J.; Parry, S.; Lord, C. J.; Ashworth, A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 2009, 1, 323-337.
128. Burris, H. A.,3rd; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D.; Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
129. Berlin, J. D.; Catalano, P.; Thomas, J. P.; Kugler, J. W.; Haller, D. G.; Benson, A. B.,3rd Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002, 20, 3270-3275. (Pubitemid 34831525)
130. Trouilloud, I.; Dubreuil, O.; Boussaha, T.; Lepere, C.; Landi, B.; Zaanan, A.; Bachet, J. B.; Taieb, J. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin. Res. Hepatol. Gastroenterol. 2011, 35, 364-374.
131. Reni, M.; Cordio, S.; Milandri, C.; Passoni, P.; Bonetto, E.; Oliani, C.; Luppi, G.; Nicoletti, R.; Galli, L.; Bordonaro, R.; Passardi, A.; Zerbi, A.; Balzano, G.; Aldrighetti, L.; Staudacher, C.; Villa, E.; Di Carlo, V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005, 6, 369-376. (Pubitemid 40753742)
132. Vulfovich, M.; Rocha-Lima, C. Novel advances in pancreatic cancer treatment. Expert Rev. Anticancer Ther. 2008, 8, 993-1002.
133. Bergman, A. M.; Pinedo, H. M.; Peters, G. J. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002, 5, 19-33.
134. Sheikh, R.; Walsh, N.; Clynes, M.; O'Connor, R.; McDermott, R. Challenges of drug resistance in the management of pancreatic cancer. Expert Rev. Anticancer Ther. 2010, 10, 1647-1661.
135. Azorsa, D. O.; Gonzales, I. M.; Basu, G. D.; Choudhary, A.; Arora, S.; Bisanz, K. M.; Kiefer, J. A.; Henderson, M. C.; Trent, J. M.; Von Hoff, D. D.; Mousses, S. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl. Med. 2009, 7, 43.
136. Karnitz, L. M.; Flatten, K. S.; Wagner, J. M.; Loegering, D.; Hackbarth, J. S.; Arlander, S. J.; Vroman, B. T.; Thomas, M. B.; Baek, Y. U.; Hopkins, K. M.; Lieberman, H. B.; Chen, J.; Cliby, W. A.; Kaufmann, S. H. Gemcitabineinduced activation of checkpoint signaling pathways that affect tumor cell survival. Mol. Pharmacol. 2005, 68, 1636-1644. (Pubitemid 41654347)
137. Giroux, V.; Iovanna, J.; Dagorn, J. C. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J. 2006, 20, 1982-1991. (Pubitemid 44953898)
138. Matthews, D. J.; Yakes, F. M.; Chen, J.; Tadano, M.; Bornheim, L.; Clary,
139. McCabe, N.; Turner, N. C.; Lord, C. J.; Kluzek, K.; Bialkowska, A.; Swift, S.; Giavara, S.; O'Connor, M. J.; Tutt, A. N.; Zdzienicka, M. Z.; Smith, G. C.; Ashworth, A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006, 66, 8109-8115. (Pubitemid 44299177)
140. Chen, C. C.; Kennedy, R. D.; Sidi, S.; Look, A. T.; D'Andrea, A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer. 2009, 8, 24.
141. Hattori, H.; Skoulidis, F.; Russell, P.; Venkitaraman, A. R. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. Mol. Cancer. Ther. 2011, 10, 670-678.
142. Bernhard, E. J.; Stanbridge, E. J.; Gupta, S.; Gupta, A. K.; Soto, D.; Bakanauskas, V. J.; Cerniglia, G. J.; Muschel, R. J.; McKenna, W. G. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res. 2000, 60, 6597-6600.
143. Rodriguez-Viciana, P.; Warne, P. H.; Dhand, R.; Vanhaesebroeck, B.; Gout, I.; Fry, M. J.; Waterfield, M. D.; Downward, J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370, 527-532. (Pubitemid 24264918)
144. Friday, B. B.; Adjei, A. A. K-ras as a target for cancer therapy. Biochim. Biophys. Acta 2005, 1756, 127-144.
145. Weinstein, I. B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297, 63-64. (Pubitemid 34743088)
146. Solimini, N. L.; Luo, J.; Elledge, S. J. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007, 130, 986-988. (Pubitemid 47422308)
147. Luo, J.; Solimini, N. L.; Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136, 823-837.
148. Scholl, C.; Frohling, S.; Dunn, I. F.; Schinzel, A. C.; Barbie, D. A.; Kim, S. Y.; Silver, S. J.; Tamayo, P.; Wadlow, R. C.; Ramaswamy, S.; Dohner, K.; Bullinger, L.; Sandy, P.; Boehm, J. S.; Root, D. E.; Jacks, T.; Hahn, W. C.; Gilliland, D. G. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137, 821-834.
149. Babij, C.; Zhang, Y.; Kurzeja, R. J.; Munzli, A.; Shehabeldin, A.; Fernando, M.; Quon, K.; Kassner, P. D.; Ruefli-Brasse, A. A.; Watson, V. J.; Fajardo, F.; Jackson, A.; Zondlo, J.; Sun, Y.; Ellison, A. R.; Plewa, C. A.; San, M. T.; Robinson, J.; McCarter, J.; Schwandner, R.; Judd, T.; Carnahan, J.; Dussault, I. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011, 71, 5818-5826.
150. Ji, Z.; Mei, F. C.; Lory, P. L.; Gilbertson, S. R.; Chen, Y.; Cheng, X. Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer. Front. Biosci. 2009, 14, 2904-2910.
151. Yang, D.; Liu, H.; Goga, A.; Kim, S.; Yuneva, M.; Bishop, J. M. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 13836-13841.
152. Buchholz, M.; Schatz, A.; Wagner, M.; Michl, P.; Linhart, T.; Adler, G.; Gress, T. M.; Ellenrieder, V. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J. 2006, 25, 3714-3724. (Pubitemid 44264881)
153. Azzariti, A.; Bocci, G.; Porcelli, L.; Fioravanti, A.; Sini, P.; Simone, G. M.; Quatrale, A. E.; Chiarappa, P.; Mangia, A.; Sebastian, S.; Del Bufalo, D.; Del Tacca, M.; Paradiso, A. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br. J. Cancer 2011, 104, 769-780.
154. Hoffman, R. M. Clinical practice. Screening for prostate cancer. N. Engl. J. Med. 2011, 365, 2013-2019.
155. Gonzalez-Guerrico, A. M.; Meshki, J.; Xiao, L.; Benavides, F.; Conti, C. J.; Kazanietz, M. G. Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. J. Biochem. Mol. Biol. 2005, 38, 639-645. (Pubitemid 43240967)
156. Zhu, T.; Tsuji, T.; Chen, C. Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras. Oncogene 2010, 29, 1050-1061.
157. Zhu, T.; Chen, L.; Du, W.; Tsuji, T.; Chen, C. Synthetic Lethality Induced by Loss of PKC delta and Mutated Ras. Genes Cancer. 2010, 1, 142-151.
158. Guo, J.; Zhu, T.; Chen, L.; Nishioka, T.; Tsuji, T.; Xiao, Z. X.; Chen, C. Y. Differential sensitization of different prostate cancer cells to apoptosis. Genes Cancer. 2010, 1, 836-846.
159. Fujii, T.; Garcia-Bermejo, M. L.; Bernabo, J. L.; Caamano, J.; Ohba, M.; Kuroki, T.; Li, L.; Yuspa, S. H.; Kazanietz, M. G. Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. J. Biol. Chem. 2000, 275, 7574-7582. (Pubitemid 30159656)
160. Turcotte, S.; Sutphin, P. D.; Giaccia, A. J. Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death. Autophagy 2008, 4, 944-946.
161. Chan, D. A.; Giaccia, A. J. Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. Cell. Cycle 2008, 7, 2987-2990.
162. Grubb, R. L.,3rd; Franks, M. E.; Toro, J.; Middelton, L.; Choyke, L.; Fowler, S.; Torres-Cabala, C.; Glenn, G. M.; Choyke, P.; Merino, M. J.; Zbar, B.; Pinto, P. A.; Srinivasan, R.; Coleman, J. A.; Linehan, W. M. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J. Urol. 2007, 177, 2074-9; discussion 2079-80.
163. Kiuru, M.; Launonen, V. Hereditary leiomyomatosis and renal cell cancer (HLRCC). Curr. Mol. Med. 2004, 4, 869-875. (Pubitemid 39585732)
164. Patel, P. H.; Chadalavada, R. S.; Chaganti, R. S.; Motzer, R. J. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin. Cancer Res. 2006, 12, 7215-7220. (Pubitemid 46095391)
165. Sourbier, C.; Valera-Romero, V.; Giubellino, A.; Yang, Y.; Sudarshan, S.; Neckers, L.; Linehan, W. M. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell. Cycle 2010, 9, 4183-4189.
166. Frezza, C.; Zheng, L.; Folger, O.; Rajagopalan, K. N.; MacKenzie, E. D.; Jerby, L.; Micaron;i, M.; Chaneton, B.; Adam, J.; Hedley, A.; Kalna, G.; Tomlinson, I. P.; Pollard, P. J.; Watson, D. G.; Deberardinis, R. J.; Shlomi, T.; Ruppin, E.; Gottlieb, E. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011, 477, 225-228.
167. Ji, Z.; Flaherty, K. T.; Tsao, H. Targeting the RAS pathway in melanoma. Trends Mol. Med. 2011.
168. Garbe, C.; Eigentler, T. K.; Keilholz, U.; Hauschild, A.; Kirkwood, J. M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011, 16, 5-24.
169. Mocellin, S.; Pasquali, S.; Rossi, C. R.; Nitti, D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and metaanalysis. J. Natl. Cancer Inst. 2010, 102, 493-501.
170. Wu, S.; Singh, R. K. Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr. Mol. Med. 2011, 11, 553-563.
171. Qin, J. Z.; Stennett, L.; Bacon, P.; Bodner, B.; Hendrix, M. J.; Seftor, R. E.; Seftor, E. A.; Margaryan, N. V.; Pollock, P. M.; Curtis, A.; Trent, J. M.; Bennett, F.; Miele, L.; Nickoloff, B. J. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol. Cancer. Ther. 2004, 3, 895-902 (Pubitemid 39199584)
172. Nickoloff, B. J.; Osborne, B. A.; Miele, L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003, 22, 6598-6608. (Pubitemid 37372340)